Literature DB >> 6281084

Stimulus properties of opioids with mixed agonist and antagonist activity.

S G Holtzman.   

Abstract

The discriminative stimulus properties of opioids with mixed agonist and antagonist activity are heterogeneous in contrast to the relative uniformity of the stimulus properties of classical morphinelike agonists. Patterns of stimulus generalization to mixed agonist-antagonists are critically dependent on factors such as the particular drug used for training, dose of the training drug, and species of the experimental subject. Opioids can be divided into three broad categories on the basis of their patterns of stimulus generalization in rats and squirrel monkeys trained to discriminate saline from morphine, cyclazocine, or phenyclidine (PCP), and these categories predict the ease with which their stimulus effects can be blocked by nalozone or naltrexone. 1) Opioids that are generalized completely to morphine; stimulus effects are easily antagonized. 2) Opioids that are generalized completely to cyclazocine; stimulus effects are antagonized with difficulty. 3) Opioids that are generalized completely to cyclazocine and PCP; stimulus effects not antagonized. The diversity of the stimulus properties of opioids is consistent with evidence that multiple populations of receptors subserve the actions of morphinelike agonists and agonist-antagonists. However, the stimulus effects of opioids in group 3 appear to be mediated by the same neuronal substrates that are acted on by PCP rather than by neuronal sites traditionally associated with the activity of opioids.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281084

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  10 in total

1.  In vivo pharmacological resultant analysis reveals noncompetitive interactions between opioid antagonists in the rat tail-withdrawal assay.

Authors:  E A Walker
Journal:  Br J Pharmacol       Date:  2006-10-30       Impact factor: 8.739

2.  Agonist and antagonist effects of prototype opiate drugs in fentanyl dose-dose discrimination.

Authors:  F C Colpaert; P A Janssen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Drug discrimination training with a single choice trial per session.

Authors:  A Tomie; E Loukas; I Stafford; L Peoples; G C Wagner
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 4.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1982-1983.

Authors:  I P Stolerman; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

5.  Opiate states of memory: receptor mechanisms.

Authors:  L A Bruins Slot; F C Colpaert
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

6.  Effects of prior saline-morphine discrimination by pigeons on three-way discrimination including two morphine doses.

Authors:  D V Gauvin; A M Young
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat.

Authors:  F C Colpaert; T F Meert; C J Niemegeers; P A Janssen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Additional evidence that L-5-hydroxytryptophan discrimination models a unique serotonin receptor.

Authors:  R Friedman; R J Barrett; E Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Antagonism of the discriminative effects of ethylketazocine, cyclazocine, and nalorphine in macaques.

Authors:  A M Young; K R Stephens
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Morphine-like discriminative stimulus effects of opioid peptides: possible modulatory role of D-Ala2-D-Leu5-enkephalin (DADL) and dynorphin A (1-13).

Authors:  M Ukai; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.